Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | POLQ | O75417 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16739580 | 0.96 | POLB (0.62) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL13160725 | 0.76 | POLB (0.53) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL17010685 | 0.75 | POLB (0.38) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL12335143 | 0.74 | POLB (0.52) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL14738537 | 0.74 | POLB (0.52) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL3610756 | 0.74 | POLB (0.52) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL3618209 | 0.74 | POLB (0.47) | GAAPOLBCYP1A2MAPTTDP1 | |
| Tetrydamine SCHEMBL43249 | 0.72 | GAA (1.00) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL23062881 | 0.72 | POLB (0.93) | GAAPOLBCYP1A2MAPTTDP1 | |
| SCHEMBL13145631 | 0.72 | GAA (0.65) | GAAPOLBCYP1A2MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2088861-A2 | BENZIMIDAZOLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008051533-A2 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | HRH4, SSTR5, CNR1 | GAA 3553/4885POLB 3990/4885CYP1A2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.